GHCM
IMDZ

Glen Harbor Capital Management’s Immune Design Corp. IMDZ Stock Holding History

Glen Harbor Capital Management’s Portfolio IMDZ Stock Details IMDZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10,710
Closed -$49K – 1317
2018
Q2 		$49K Buy
+10,710
New +$42.7K ﹤0.01% 1219

Other funds holding IMDZ

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Glen Harbor Capital Management's IMDZ Position: Q3 2018 in Review

Glen Harbor Capital Management sold out of Immune Design Corp. (IMDZ) in Q3 2018, closing a stake of 10,710 shares — an estimated $49K sold.

Glen Harbor Capital Management first reported a position in IMDZ in Q2 2018 and held it in 1 quarter. The position peaked at $49K in Q2 2018. 71 funds tracked by Wall St. Rank hold IMDZ as of Q3 2018.

  • Glen Harbor Capital Management reported no remaining Immune Design Corp. position as of Q3 2018 after selling out during the quarter.
  • Glen Harbor Capital Management sold 10,710 Immune Design Corp. shares in Q3 2018, an estimated $49K.
  • Glen Harbor Capital Management first reported a position in Immune Design Corp. in Q2 2018 and held it in 1 quarter.
  • Glen Harbor Capital Management's Immune Design Corp. position peaked at $49K in Q2 2018.
  • 71 funds tracked by Wall St. Rank held Immune Design Corp. as of Q3 2018.

Based on Glen Harbor Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.